
Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.

The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.